Clinical Trials Logo

Ischemia clinical trials

View clinical trials related to Ischemia.

Filter by:
  • Not yet recruiting  
  • « Prev · Page 27

NCT ID: NCT00922389 Not yet recruiting - Diabetic Foot Clinical Trials

A Clinical Trial on Diabetic Foot Using Peripheral Blood Derived Stem Cells for Treating Critical Limb Ischemia

Start date: July 2009
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to determine whether the method (implanting stem cells derived from peripheral blood after G-CSF mobilization) of treatment is safe and effective in the management of diabetic foot ischemia, the therapeutic effect of stem cells is caused by improving blood circulation in ischemic limb which would in turn promote ulcer healing, prevent amputation of limb and relieve the Sevier pain of ischemia.

NCT ID: NCT00821158 Not yet recruiting - Clinical trials for Ischemia-Reperfusion

The DIEP Flap as a Model of Ischemia-Reperfusion: an Intervention Study

Start date: February 2009
Phase: Phase 3
Study type: Interventional

The investigators will examine whether administration of certain medications will decrease or prevent ischemia-reperfusion injury.

NCT ID: NCT00691613 Not yet recruiting - Clinical trials for Myocardial Infarction

Infusion of a Single Dose of Erythropoietin to Prevent Injury in an Ischemia Reperfusion Forearm Model

IPIIR
Start date: July 2010
Phase: N/A
Study type: Interventional

Rationale: The investigators hypothesize that EPO protects against apoptosis after acute ischemia in man and that it is detectable using the annexin-A5 model. Objective: Does infusion of a single dose of Epoetin Alfa, a short-acting EPO, protect against apoptosis in man after acute ischemia? Study design: A double blinded randomised cross-over study. Study population: 12 Healthy male volunteers, between 18 and 40 years old. Intervention: All 12 volunteers will receive a single dose of EPO and placebo in a randomized order. A six week wash-out period is obtained in order to avoid interference of both treatments. Main study parameters/endpoints: The percentage of difference between radioactivity (quantified as counts per pixel) of the experimental and control thenar muscle at one and four hours after reperfusion.

NCT ID: NCT00547950 Not yet recruiting - Ischemic Stroke Clinical Trials

A Multiple-Centered, Prospective Cohort Study: the Second Prevention Trial for Ischemic Stroke With Deng Zhan Sheng Mai Capsule(SPIRIT—DZSM-2)

Start date: November 2007
Phase: N/A
Study type: Interventional

In order to observe the influence of the Dengzhan Shengmai Capsule on the endpoint of patients with ischemic stroke, we hold the multi-centered prospective cohort study. From November 2007 to December 2009, 12000 subjects are included in 200 clinical research centers all over China. The subjects naturally formed two cohorts based on taking Dengzhan Shengmai capsule or not. The basic therapy included antiplatelet aggregation , stroke health education, management of blood pressure, blood lipid and blood glucose, etc. Then all of the subjects are visited on the 360th day after inclusion. The recurrence of stroke, cardiovascular events, and peripheral arterial events are observed.

NCT ID: NCT00117936 Not yet recruiting - Coronary Disease Clinical Trials

Fibroblast Growth Factor-1 (FGF-1) for the Treatment of Coronary Heart Disease

Start date: March 2020
Phase: Phase 2
Study type: Interventional

Treatment for no-option heart patients with coronary artery disease. Procedure includes the injection into the heart of a protein growth factor, administered by the Biological Delivery Systems MyoStar injection and mapping catheters, to stimulate the growth of blood vessels around blocked coronary arteries.